Clinical Study
Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy
Table 4
Within- and between-group comparisons of relative changes (%) in lipid profile and tumor necrosis factor-alpha (TNF-) serum level at 4 and 24 weeks.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ETA + MTX: etanercept plus methotrexate; MTX: methotrexate as monotherapy; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation. Absolute change is the difference at 4 or 24 weeks versus baseline; relative change is the percentage change at 4 or 24 weeks versus baseline values. : relative change between groups is a comparison of the differences in relative change (%) at 4 and 24 weeks between groups. The values for the calculations were obtained with unpaired Student’s tests. Intragroup comparisons between 4 and 24 weeks versus baseline were calculated with paired Student’s -tests. * , **, †, and ‡. |